Large, multinational cohort suggests ondansetron use in pregnancy does not increase the risk for adverse fetal outcomes.

Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort – JAMA Network Open

Editorial: Providing Data to Empower Pregnant Patients to Make Evidence-Based Choices

Related: Cohort Study: Maternal Ondansetron Use and Risk of Cardiac Malformations and Oral Clefts in Offspring

Commentary on Twitter

This cohort study found there was no association between ondansetron exposure during pregnancy and increased risk of fetal death, spontaneous abortion, stillbirth, or major congenital malformations compared with exposure to other antiemetic drugs. https://t.co/hDXr72Ga01

— JAMA Network Open (@JAMANetworkOpen) April 23, 2021